{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:53:47Z","timestamp":1791827627006,"version":"4.3.4"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01190-3","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:42:39Z","timestamp":1791826959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on testosterone deficiency and therapeutic options for testosterone replacement therapy"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-8954","authenticated-orcid":false,"given":"Thomas","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-999X","authenticated-orcid":false,"given":"Mohamed","family":"Mubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Hugh","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Modgil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"1190_CR1","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","volume":"103","author":"S Bhasin","year":"2018","unstructured":"Bhasin, S. et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 1715\u20131744 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/sxmrev\/qeaf036","volume":"13","author":"M Khera","year":"2025","unstructured":"Khera, M. et al. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex. Med. Rev. 13, 548\u2013573 (2025).","journal-title":"Sex. Med. Rev."},{"key":"1190_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eururo.2021.06.007","volume":"80","author":"A Salonia","year":"2021","unstructured":"Salonia, A. et al. European Association of Urology guidelines on sexual and reproductive health \u2014 2021 update: male sexual dysfunction. Eur. Urol. 80, 333\u2013357 https:\/\/doi.org\/10.1016\/j.eururo.2021.06.007 (2021).","journal-title":"Eur. Urol."},{"key":"1190_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","volume":"200","author":"JP Mulhall","year":"2018","unstructured":"Mulhall, J. P. et al. Evaluation and management of testosterone deficiency: AUA guideline. J. Urol. 200, 423\u2013432 (2018).","journal-title":"J. Urol."},{"key":"1190_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5534\/wjmh.221027","volume":"41","author":"G Hackett","year":"2023","unstructured":"Hackett, G. et al. The British Society for Sexual Medicine guidelines on male adult testosterone deficiency, with statements for practice. World J. Mens Health 41, 508\u2013537 https:\/\/doi.org\/10.5534\/wjmh.221027 (2023).","journal-title":"World J. Mens Health"},{"key":"1190_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/andr.12459","volume":"6","author":"SJ Winters","year":"2018","unstructured":"Winters, S. J., Moore, J. P. Jr & Clark, B. J. Leydig cell insufficiency in hypospermatogenesis: a paracrine effect of activin\u2013inhibin signalling? Andrology 6, 262\u2013271 https:\/\/doi.org\/10.1111\/andr.12459 (2018).","journal-title":"Andrology"},{"key":"1190_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/andr.12909","volume":"9","author":"M Zitzmann","year":"2021","unstructured":"Zitzmann, M. et al. European Academy of Andrology guidelines on Klinefelter syndrome: endorsing organization: European Society of Endocrinology. Andrology 9, 145\u2013167 https:\/\/doi.org\/10.1111\/andr.12909 (2021).","journal-title":"Andrology"},{"key":"1190_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1210\/jc.2016-3580","volume":"102","author":"M Grossmann","year":"2017","unstructured":"Grossmann, M. & Matsumoto, A. M. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J. Clin. Endocrinol. Metab. 102, 1067\u20131075 https:\/\/doi.org\/10.1210\/jc.2016-3580 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","volume":"369","author":"JS Finkelstein","year":"2013","unstructured":"Finkelstein, J. S. et al. Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 369, 1011\u20131022 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0911101","volume":"363","author":"FCW Wu","year":"2010","unstructured":"Wu, F. C. W. et al. Identification of late-onset hypogonadism in middle aged and elderly men. N. Engl. J. Med. 363, 123\u2013135 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR11","doi-asserted-by":"publisher","unstructured":"Zarotsky, V. et al. Systematic literature review of the epidemiology of nongenetic forms of hypogonadism in adult males. J. Horm. https:\/\/doi.org\/10.1155\/2014\/190347 (2014).","DOI":"10.1155\/2014\/190347"},{"key":"1190_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","volume":"60","author":"T Mulligan","year":"2006","unstructured":"Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A. & McWhirter, C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 60, 762\u2013769 (2006).","journal-title":"Int. J. Clin. Pract."},{"key":"1190_CR13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1210\/jc.2007-1972","volume":"93","author":"FCW Wu","year":"2008","unstructured":"Wu, F. C. W. et al. Hypothalamic\u2013pituitary\u2013testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J. Clin. Endocrinol. Metab. 93, 2737\u20132745 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/andr.274","volume":"2","author":"V Zarotsky","year":"2014","unstructured":"Zarotsky, V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2, 819\u2013834 https:\/\/doi.org\/10.1111\/andr.274 (2014).","journal-title":"Andrology"},{"key":"1190_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cen.13038","volume":"85","author":"J Bobjer","year":"2016","unstructured":"Bobjer, J. et al. High prevalence of hypogonadism and associated impaired metabolic and bone mineral status in subfertile men. Clin. Endocrinol. 85, 189\u2013195 (2016).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR16","doi-asserted-by":"publisher","first-page":"e3410","DOI":"10.1210\/clinem\/dgaf038","volume":"110","author":"F Ahmed","year":"2025","unstructured":"Ahmed, F. et al. Altered expression of aromatase and estrogen receptors in adipose tissue from men with obesity or type 2 diabetes. J. Clin. Endocrinol. Metab. 110, e3410\u2013e3424 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrendo.2013.122","volume":"9","author":"PM Rao","year":"2013","unstructured":"Rao, P. M., Kelly, D. M. & Jones, T. H. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat. Rev. Endocrinol. 9, 479\u2013493 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1190_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/BF03345527","volume":"28","author":"LA Heinemann","year":"2005","unstructured":"Heinemann, L. A. Aging Males\u2019 Symptoms scale: a standardized instrument for the practice. J. Endocrinol. Invest. 28, 34\u201338 (2005).","journal-title":"J. Endocrinol. Invest."},{"key":"1190_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/ijir.2009.35","volume":"22","author":"O Mohamed","year":"2010","unstructured":"Mohamed, O. et al. The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. Int. J. Impot. Res. 22, 20\u201324 (2010).","journal-title":"Int. J. Impot. Res."},{"key":"1190_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.sxmr.2019.06.003","volume":"7","author":"A Morgentaler","year":"2019","unstructured":"Morgentaler, A. et al. Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 International Consultation for Sexual Medicine. Sex. Med. Rev. 7, 636\u2013649 (2019).","journal-title":"Sex. Med. Rev."},{"key":"1190_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/cen.14633","volume":"96","author":"CN Jayasena","year":"2022","unstructured":"Jayasena, C. N. et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin. Endocrinol. 96, 200\u2013219 (2022).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/00045632231179022","volume":"60","author":"CN Jayasena","year":"2023","unstructured":"Jayasena, C. N. et al. Standardising the biochemical confirmation of adult male hypogonadism; a joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine. Ann. Clin. Biochem. 60, 223\u2013227 (2023).","journal-title":"Ann. Clin. Biochem."},{"key":"1190_CR23","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","volume":"84","author":"A Vermeulen","year":"1999","unstructured":"Vermeulen, A., Verdonck, L. & Kaufman, J. M. A critical evaluation of simple methods for the estfimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666\u20133672 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/eje.0.1510241","volume":"151","author":"PD Morris","year":"2004","unstructured":"Morris, P. D., Malkin, C. J., Channer, K. S. & Jones, T. H. A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur. J. Endocrinol. 151, 241\u2013249 (2004).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR25","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1210\/jcem-56-6-1278","volume":"56","author":"WJ Bremner","year":"1983","unstructured":"Bremner, W. J., Vitiello, M. V. & Prinz, P. N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J. Clin. Endocrinol. Metab. 56, 1278\u20131281 (1983).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR26","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1210\/jc.2008-1902","volume":"94","author":"DJ Brambilla","year":"2009","unstructured":"Brambilla, D. J. et al. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J. Clin. Endocrinol. Metab. 94, 907\u2013913 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1046\/j.1365-2265.2003.01772.x","volume":"58","author":"MJ Diver","year":"2003","unstructured":"Diver, M. J., Imtiaz, K. E., Ahmad, A. M., Vora, J. P. & Fraser, W. D. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin. Endocrinol. 58, 710\u2013717 (2003).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1464-410X.2007.07022.x","volume":"100","author":"ED Crawford","year":"2007","unstructured":"Crawford, E. D. et al. The association of time of day and serum testosterone concentration in a large screening population. BJU Int. 100, 509\u2013513 (2007).","journal-title":"BJU Int."},{"key":"1190_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.eururo.2017.03.032","volume":"72","author":"G Corona","year":"2017","unstructured":"Corona, G. et al. Meta-analysis of the results of testosterone therapy on sexual function based on the IIEF scores. Eur. Urol. 72, 1000\u20131011 (2017).","journal-title":"Eur. Urol."},{"key":"1190_CR30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2337\/dc10-1233","volume":"34","author":"TH Jones","year":"2011","unstructured":"Jones, T. H. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study). Diabetes Care 34, 828\u2013837 (2011).","journal-title":"Diabetes Care"},{"key":"1190_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/bju.13516","volume":"118","author":"G Hackett","year":"2016","unstructured":"Hackett, G. et al. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. BJU Int. 118, 804\u2013813 (2016).","journal-title":"BJU Int."},{"key":"1190_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","volume":"374","author":"PJ Snyder","year":"2016","unstructured":"Snyder, P. J. et al. Effects of testosterone treatment in older men. N. Engl. J. Med. 374, 611\u2013624 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR33","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1210\/jc.2016-1645","volume":"101","author":"GR Cunningham","year":"2016","unstructured":"Cunningham, G. R. et al. Testosterone treatment and sexual function in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 101, 3096\u201330104 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1210\/clinem\/dgad484","volume":"109","author":"KM Pencina","year":"2024","unstructured":"Pencina, K. M. et al. Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism. J. Clin. Endocrinol. Metab. 109, 569\u2013580 https:\/\/doi.org\/10.1210\/clinem\/dgad484 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Cardiovascular safety of testosterone-replacement therapy. N. Engl. J. Med. 389, 107\u2013117 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR36","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/andr.12399","volume":"5","author":"Hackett","year":"2017","unstructured":"Hackett et al. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology 5, 905\u2013913 (2017).","journal-title":"Andrology"},{"key":"1190_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.21037\/tau.2020.01.13","volume":"9","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Transl. Androl. Urol. 9, 591\u2013600 https:\/\/doi.org\/10.21037\/tau.2020.01.13 (2020).","journal-title":"Transl. Androl. Urol."},{"key":"1190_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1743-6109.2010.01956.x","volume":"8","author":"J Buvat","year":"2011","unstructured":"Buvat, J. et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J. Sex. Med. 8, 284\u2013293 (2011).","journal-title":"J. Sex. Med."},{"key":"1190_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/01.ju.0000132389.97804.d7","volume":"172","author":"R Shabsigh","year":"2004","unstructured":"Shabsigh, R., Kaufman, J. M., Steidle, C. & Padma-Nathan, H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J. Urol. 172, 658\u2013663 (2004).","journal-title":"J. Urol."},{"key":"1190_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","volume":"9","author":"G Wittert","year":"2021","unstructured":"Wittert, G. et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 9, 32\u201345 https:\/\/doi.org\/10.1016\/S2213-8587(20)30367-3 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1190_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","volume":"177","author":"CN Roy","year":"2017","unstructured":"Roy, C. N. et al. Association of tesosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern. Med. 177, 480\u2013490 (2017).","journal-title":"JAMA Intern. Med."},{"key":"1190_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40030","volume":"6","author":"KM Pencina","year":"2023","unstructured":"Pencina, K. M. et al. Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial. JAMA Netw. Open 6, e2340030 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1190_CR43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.juro.2015.10.130","volume":"195","author":"LT Zhang","year":"2016","unstructured":"Zhang, L. T. et al. Could testosterone replacement therapy in hypogonadal men ameliorate anemia, a cardiovascular risk factor? An observational, 54-week cumulative registry study. J. Urol. 195, 1057\u20131064 (2016).","journal-title":"J. Urol."},{"key":"1190_CR44","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1210\/jc.2009-0206","volume":"94","author":"ES LeBlanc","year":"2009","unstructured":"LeBlanc, E. S. et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab. 94, 3337\u20133346 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/ki.2010.161","volume":"78","author":"J Meng","year":"2010","unstructured":"Meng, J. et al. Associations of estradiol and testosterone with serum phosphorus in older men: the osteoporotic fractures in men study. Kidney Int. 78, 415\u2013422 (2010).","journal-title":"Kidney Int."},{"key":"1190_CR46","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/jbmr.3088","volume":"32","author":"L Vandenput","year":"2017","unstructured":"Vandenput, L. et al. Low testosterone, but not estradiol, is associated with incident falls in older men: the international MrOS study. J. Bone Miner. Res. 32, 1174\u20131181 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"1190_CR47","doi-asserted-by":"publisher","first-page":"e3143","DOI":"10.1210\/clinem\/dgab149","volume":"106","author":"MNT Fui","year":"2021","unstructured":"Fui, M. N. T. et al. Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a two-year RCT. J. Clin. Endocrinol. Metab. 106, e3143\u2013e3158 https:\/\/doi.org\/10.1210\/clinem\/dgab149 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR48","doi-asserted-by":"publisher","unstructured":"Snyder, P. J. et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern. Med. 177, 471\u2013479 https:\/\/doi.org\/10.1001\/jamainternmed.2016.9539 (2017). Erratum in: JAMA Intern. Med.\u00a0177, 600 (2017). Erratum in: JAMA Intern. Med. 179, 457 (2019).","DOI":"10.1001\/jamainternmed.2016.9539"},{"key":"1190_CR49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2308836","volume":"390","author":"PJ Snyder","year":"2024","unstructured":"Snyder, P. J. et al. Testosterone treatment and fractures in men with hypogonadism. N. Engl. J. Med. 390, 203\u2013211 https:\/\/doi.org\/10.1056\/NEJMoa2308836 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR50","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.juro.2013.10.070","volume":"191","author":"R Kacker","year":"2014","unstructured":"Kacker, R. et al. Bone mineral density and response to treatment in men younger than 50 years with testosterone deficiency and sexual dysfunction or infertility. J. Urol. 191, 1072\u20131076 (2014).","journal-title":"J. Urol."},{"key":"1190_CR51","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2265.2005.02339.x","volume":"63","author":"AM Isidori","year":"2005","unstructured":"Isidori, A. M. et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin. Endocrinol. 63, 280\u2013293 (2005).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR52","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1210\/jc.2004-1933","volume":"90","author":"ST Page","year":"2005","unstructured":"Page, S. T. et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J. Clin. Endocrinol. Metab. 90, 1502\u20131510 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR53","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/ijir.2008.19","volume":"20","author":"J Svartberg","year":"2008","unstructured":"Svartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T. & Jorde, R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int. J. Impot. Res. 20, 378\u2013387 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"1190_CR54","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1210\/jc.2013-3665","volume":"99","author":"M Al Mukaddam","year":"2014","unstructured":"Al Mukaddam, M. et al. Effects of testosterone and growth hormone on the structural and mechanical properties of bone by micro-MRI in the distal tibia of men with hypopituitarism. J. Clin. Endocrinol. Metab. 99, 1236\u20131244 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1365-2265.2001.01271.x","volume":"54","author":"C Wang","year":"2001","unstructured":"Wang, C. et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. 54, 739\u2013750 (2001).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1210\/jc.2003-031110","volume":"89","author":"JK Amory","year":"2004","unstructured":"Amory, J. K. et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503\u2013510 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR57","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.steroids.2008.10.003","volume":"74","author":"BL Clarke","year":"2009","unstructured":"Clarke, B. L. & Khosla, S. Androgens and bone. Steroids 74, 296\u2013305 (2009).","journal-title":"Steroids"},{"key":"1190_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3803\/EnM.2014.29.1.48","volume":"29","author":"MJ Lee","year":"2014","unstructured":"Lee, M. J. et al. Testosterone replacement and bone mineral density in male pituitary tumor patients. Endocrinol. Metab. 29, 48\u201353 (2014).","journal-title":"Endocrinol. Metab."},{"key":"1190_CR59","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3349\/ymj.2013.54.6.1331","volume":"54","author":"DG Jo","year":"2013","unstructured":"Jo, D. G. et al. Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Med. J. 54, 1331\u20131335 (2013).","journal-title":"Yonsei Med. J."},{"key":"1190_CR60","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/MOU.0000000000000104","volume":"24","author":"MS Irwig","year":"2014","unstructured":"Irwig, M. S. Bone health in hypogonadal men. Curr. Opin. Urol. 24, 608\u2013613 (2014).","journal-title":"Curr. Opin. Urol."},{"key":"1190_CR61","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1210\/jc.2006-0036","volume":"91","author":"MJ Tracz","year":"2006","unstructured":"Tracz, M. J. et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J. Clin. Endocrinol. Metab. 91, 2011\u20132016 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR62","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1530\/JOE-12-0455","volume":"217","author":"DM Kelly","year":"2013","unstructured":"Kelly, D. M. & Jones, T. H. Testosterone: a metabolic hormone in health and disease. J. Endocrinol. 217, R25\u2013R45 (2013).","journal-title":"J. Endocrinol."},{"key":"1190_CR63","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/j.1365-2605.2010.01117.x","volume":"34","author":"G Corona","year":"2011","unstructured":"Corona, G. et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int. J. Androl. 34, 528\u2013540 (2011).","journal-title":"Int. J. Androl."},{"key":"1190_CR64","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1743-6109.2010.01991.x","volume":"8","author":"G Corona","year":"2011","unstructured":"Corona, G. et al. Testosterone and metabolic syndrome: a meta-analysis study. J. Sex. Med. 8, 272\u2013283 (2011).","journal-title":"J. Sex. Med."},{"key":"1190_CR65","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1210\/jc.2004-0970","volume":"90","author":"DE Laaksonen","year":"2005","unstructured":"Laaksonen, D. E. et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J. Clin. Endocrinol. Metab. 90, 712\u2013719 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR66","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11154-015-9323-2","volume":"16","author":"AM Traish","year":"2015","unstructured":"Traish, A. M. & Zitzmann, M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev. Endocr. Metab. Disord. 16, 249\u2013268 (2015).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1190_CR67","first-page":"407","volume":"82","author":"S Bhasin","year":"1997","unstructured":"Bhasin, S. et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 407\u2013413 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR68","first-page":"3469","volume":"81","author":"IG Brodsky","year":"1996","unstructured":"Brodsky, I. G., Balagopal, P. & Nair, K. S. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men \u2014 a clinical research center study. J. Clin. Endocrinol. Metab. 81, 3469\u20133475 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR69","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1210\/jc.2003-031492","volume":"89","author":"LJ Woodhouse","year":"2004","unstructured":"Woodhouse, L. J. et al. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J. Clin. Endocrinol. Metab. 89, 718\u2013726 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR70","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1210\/jc.2009-1251","volume":"95","author":"U Srinivas-Shankar","year":"2010","unstructured":"Srinivas-Shankar, U. et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 95, 639\u2013650 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1000485","volume":"363","author":"S Basaria","year":"2010","unstructured":"Basaria, S. et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363, 109\u2013122 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR72","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa054629","volume":"355","author":"KS Nair","year":"2006","unstructured":"Nair, K. S. et al. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl. J. Med. 355, 1647\u20131659 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1190_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2007.51","volume":"299","author":"MH Emmelot-Vonk","year":"2008","unstructured":"Emmelot-Vonk, M. H. et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299, 39\u201352 (2008).","journal-title":"JAMA"},{"key":"1190_CR74","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jsxm.2016.06.003","volume":"13","author":"S Permpongkosol","year":"2016","unstructured":"Permpongkosol, S. et al. Effects of 8-year treatment of long acting testosterone undecanoate on metabolic parameters, urinary symptoms, bone mineral density, and sexual function in men with late-onset hypogonadism. J. Sex. Med. 13, 1199\u20131211 (2016).","journal-title":"J. Sex. Med."},{"key":"1190_CR75","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1530\/eje.1.02166","volume":"154","author":"D Kapoor","year":"2006","unstructured":"Kapoor, D., Goodwin, E., Channer, K. S. & Jones, T. H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 154, 899\u2013906 (2006).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/dc15-1518","volume":"39","author":"S Dhindsa","year":"2016","unstructured":"Dhindsa, S. et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care 39, 82\u201391 (2016).","journal-title":"Diabetes Care"},{"key":"1190_CR77","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jsm.12404","volume":"11","author":"G Hackett","year":"2014","unstructured":"Hackett, G. et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with co-existing depression: the BLAST study. J. Sex. Med. 11, 840\u2013856 (2014).","journal-title":"J. Sex. Med."},{"key":"1190_CR78","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1365-2265.2010.03845.x","volume":"73","author":"SY Kalinchenko","year":"2010","unstructured":"Kalinchenko, S. Y. et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin. Endocrinol. 73, 602\u2013612 (2010).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR79","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13685538.2018.1468429","volume":"21","author":"K Groti","year":"2018","unstructured":"Groti, K., Zuran, I., Antonic, B., Forsnaric, L. & Pfeifer, M. The impactof testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese men with type 2 diabetes. Aging Male 21, 158\u2013169 (2018).","journal-title":"Aging Male"},{"key":"1190_CR80","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ijcp.12319","volume":"68","author":"AM Traish","year":"2014","unstructured":"Traish, A. M. et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 68, 314\u2013329 (2014).","journal-title":"Int. J. Clin. Pract."},{"key":"1190_CR81","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ijo.2015.139","volume":"40","author":"F Saad","year":"2016","unstructured":"Saad, F. et al. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int. J. Obes. 40, 162\u2013170 (2016).","journal-title":"Int. J. Obes."},{"key":"1190_CR82","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1530\/EJE-15-0262","volume":"174","author":"G Corona","year":"2016","unstructured":"Corona, G. et al. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur. J. Endocrinol. 174, R99\u2013R116 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR83","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamainternmed.2023.7862","volume":"184","author":"S Bhasin","year":"2024","unstructured":"Bhasin, S. et al. Effect of progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial. JAMA Intern. Med. 184, 353\u2013362 (2024).","journal-title":"JAMA Intern. Med."},{"key":"1190_CR84","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/dom.14122","volume":"22","author":"KS Haider","year":"2020","unstructured":"Haider, K. S. et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes. Metab. 22, 2055\u20132068 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"1190_CR85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/104012371402600103","volume":"26","author":"HR Amanatkar","year":"2014","unstructured":"Amanatkar, H. R. et al. Impact of exogenous testosterone on mood: a systematic review and metaanalysis of randomized placebo-controlled trials. Ann. Clin. Psychiatry 26, 19\u201332 (2014).","journal-title":"Ann. Clin. Psychiatry"},{"key":"1190_CR86","doi-asserted-by":"publisher","DOI":"10.1111\/and.12630","volume":"49","author":"Y Nian","year":"2017","unstructured":"Nian, Y. et al. Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: a meta-analysis of randomized controlled trials. Andrologia 49, e12630 https:\/\/doi.org\/10.1111\/and.12630 (2017).","journal-title":"Andrologia"},{"key":"1190_CR87","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1111\/j.1743-6109.2010.01859.x","volume":"7","author":"EJ Giltay","year":"2010","unstructured":"Giltay, E. J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J. Sex. Med. 7, 2572\u20132582 (2010).","journal-title":"J. Sex. Med."},{"key":"1190_CR88","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MOU.0000000000000256","volume":"26","author":"M Khera","year":"2016","unstructured":"Khera, M. Male hormones and men\u2019s quality of life. Curr. Opin. Urol. 26, 152\u2013157 (2016).","journal-title":"Curr. Opin. Urol."},{"key":"1190_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/13685538.2013.858113","volume":"17","author":"C Pexman-Fieth","year":"2014","unstructured":"Pexman-Fieth, C. et al. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. Aging Male 17, 1\u201311 (2014).","journal-title":"Aging Male"},{"key":"1190_CR90","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1210\/clinem\/dgae026","volume":"109","author":"S Bhasin","year":"2024","unstructured":"Bhasin, S. et al. Depressive syndromes in men with hypogonadism in the TRAVERSE trial: response to testosterone-replacement therapy. J. Clin. Endocrinol. Metab. 109, 1814\u20131826 https:\/\/doi.org\/10.1210\/clinem\/dgae026 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR91","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1001\/jama.2015.8881","volume":"314","author":"S Basaria","year":"2015","unstructured":"Basaria, S. et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 314, 570\u2013581 (2015).","journal-title":"JAMA"},{"key":"1190_CR92","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2016.21044","volume":"317","author":"SM Resnick","year":"2017","unstructured":"Resnick, S. M. et al. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA 317, 717\u2013727 (2017).","journal-title":"JAMA"},{"key":"1190_CR93","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S2213-8587(16)30102-4","volume":"4","author":"G Huang","year":"2016","unstructured":"Huang, G. et al. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial. Lancet Diabetes Endocrinol. 4, 657\u2013665 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1190_CR94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/ehi443","volume":"27","author":"CJ Malkin","year":"2006","unstructured":"Malkin, C. J. et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57\u201364 (2006).","journal-title":"Eur. Heart J."},{"key":"1190_CR95","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2009.04.078","volume":"54","author":"G Caminiti","year":"2009","unstructured":"Caminiti, G. et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919\u2013927 https:\/\/doi.org\/10.1016\/j.jacc.2009.04.078 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1190_CR96","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632","volume":"5","author":"M Toma","year":"2012","unstructured":"Toma, M. et al. Testosterone supplementation in heart failure: a meta-analysis. Circ. Heart Fail. 5, 315\u2013321 (2012).","journal-title":"Circ. Heart Fail."},{"key":"1190_CR97","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0195-668X(03)00083-6","volume":"24","author":"PJ Pugh","year":"2003","unstructured":"Pugh, P. J., Jones, T. H. & Channer, K. S. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur. Heart J. 24, 909\u2013915 (2003).","journal-title":"Eur. Heart J."},{"key":"1190_CR98","first-page":"256","volume":"105","author":"MR Santos","year":"2015","unstructured":"Santos, M. R. et al. Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure. Arq. Bras. Cardiol. 105, 256\u2013264 (2015).","journal-title":"Arq. Bras. Cardiol."},{"key":"1190_CR99","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","volume":"296","author":"LS Marks","year":"2006","unstructured":"Marks, L. S. et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296, 2351\u20132361 (2006).","journal-title":"JAMA"},{"key":"1190_CR100","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.juro.2017.07.039","volume":"199","author":"KS Haider","year":"2018","unstructured":"Haider, K. S., Haider, A., Doros, G. & Traish, A. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: Results from a propensity matched subgroup of a controlled registry study. J. Urol. 199, 257\u2013265 (2018).","journal-title":"J. Urol."},{"key":"1190_CR101","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/luts.12150","volume":"10","author":"JS Shim","year":"2018","unstructured":"Shim, J. S. et al. Serum testosterone levels are negatively correlated with International Prostate Symptom Score and transitional prostate volume. Low. Urin. Tract Sympt. 10, 143\u2013147 (2018).","journal-title":"Low. Urin. Tract Sympt."},{"key":"1190_CR102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000447187","volume":"11","author":"C Yucel","year":"2017","unstructured":"Yucel, C., Keskin, M. Z. & Peskircioglu, C. L. The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Curr. Urol. 11, 4\u20138 (2017).","journal-title":"Curr. Urol."},{"key":"1190_CR103","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1210\/jcem.82.6.3988","volume":"82","author":"R Sih","year":"1997","unstructured":"Sih, R. et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 82, 1661\u20131667 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR104","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1532-5415.2010.02865.x","volume":"58","author":"AM Kenny","year":"2010","unstructured":"Kenny, A. M. et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J. Am. Geriatr. Soc. 58, 1134\u20131143 (2010).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1190_CR105","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-016-0600-8","volume":"17","author":"W Baas","year":"2016","unstructured":"Baas, W. & K\u00f6hler, T. S. Testosterone replacement therapy and BPH\/LUTS. What is the evidence? Curr. Urol. Rep. 17, 46 (2016).","journal-title":"Curr. Urol. Rep."},{"key":"1190_CR106","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.eururo.2016.01.043","volume":"69","author":"TP Kohn","year":"2016","unstructured":"Kohn, T. P. et al. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur. Urol. 69, 1083\u20131090 (2016).","journal-title":"Eur. Urol."},{"key":"1190_CR107","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1177\/1557988316652843","volume":"12","author":"K Okada","year":"2018","unstructured":"Okada, K. et al. Improved lower urinary tract symptoms associated with testosterone replacement therapy in Japanese men with late-onset hypogonadism. Am. J. Mens Health. 12, 1403\u20131408 (2018).","journal-title":"Am. J. Mens Health."},{"key":"1190_CR108","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.juro.2013.05.111","volume":"190","author":"JA Pearl","year":"2013","unstructured":"Pearl, J. A. et al. Testosterone supplementation does not worsen urinary tract symptoms. J. Urol. 190, 1828\u20131833 (2013).","journal-title":"J. Urol."},{"key":"1190_CR109","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s11255-023-03602-4","volume":"55","author":"A Yassin","year":"2023","unstructured":"Yassin, A. et al. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size. Int. Urol. Nephrol. 55, 1649\u20131658 https:\/\/doi.org\/10.1007\/s11255-023-03602-4 (2023).","journal-title":"Int. Urol. Nephrol."},{"key":"1190_CR110","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/01485010701730880","volume":"53","author":"F Saad","year":"2007","unstructured":"Saad, F. et al. An exploratory study of the effects of 12-month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch. Androl. 53, 353\u2013357 (2007).","journal-title":"Arch. Androl."},{"key":"1190_CR111","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins, C. & Hodges, C. V. Studies on prostate cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293\u2013297 (1941).","journal-title":"Cancer Res."},{"key":"1190_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103061","volume":"80","author":"A Morgentaler","year":"2025","unstructured":"Morgentaler, A. O\u2019 testosterone, where is thy sting? A urologist\u2019s reflection on testosterone and prostate cancer. EClinicalMedicine 80, 103061 (2025).","journal-title":"EClinicalMedicine"},{"key":"1190_CR113","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5534\/wjmh.2017.35.2.65","volume":"35","author":"G Corona","year":"2017","unstructured":"Corona, G. et al. Testosterone replacement therapy: long-term safety and efficacy. World J. Mens Health 35, 65\u201376 (2017).","journal-title":"World J. Mens Health"},{"key":"1190_CR114","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S2213-8587(16)00112-1","volume":"4","author":"CJ Wallis","year":"2016","unstructured":"Wallis, C. J. et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 4, 498\u2013506 (2016).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1190_CR115","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ucl.2007.08.002","volume":"34","author":"A Morgentaler","year":"2007","unstructured":"Morgentaler, A. Testosterone replacement therapy and prostate cancer. Urol. Clin. North. Am. 34, 555\u2013563 https:\/\/doi.org\/10.1016\/j.ucl.2007.08.002 (2007).","journal-title":"Urol. Clin. North. Am."},{"key":"1190_CR116","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","volume":"55","author":"A Morgentaler","year":"2009","unstructured":"Morgentaler, A. & Traish, A. M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. 55, 310\u2013320 (2009).","journal-title":"Eur. Urol."},{"key":"1190_CR117","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","volume":"69","author":"AL Kaplan","year":"2016","unstructured":"Kaplan, A. L. et al. Testosterone therapy in men with prostate cancer. Eur. Urol. 69, 894\u2013903 (2016).","journal-title":"Eur. Urol."},{"key":"1190_CR118","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.juro.2011.04.065","volume":"186","author":"M Khera","year":"2011","unstructured":"Khera, M. et al. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J. Urol. 186, 5\u201311 (2011).","journal-title":"J. Urol."},{"key":"1190_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/ijir.2008.31","volume":"21","author":"R Shabsigh","year":"2009","unstructured":"Shabsigh, R. et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int. J. Impot. Res. 21, 9\u201323 (2009).","journal-title":"Int. J. Impot. Res."},{"key":"1190_CR120","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/jsm.12429","volume":"11","author":"AL Kaplan","year":"2014","unstructured":"Kaplan, A. L. et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J. Sex. Med. 11, 1063\u20131070 (2014).","journal-title":"J. Sex. Med."},{"key":"1190_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00017","volume":"3","author":"A Aversa","year":"2012","unstructured":"Aversa, A. et al. Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: effects of 3 years intermittent testosterone supplementation. Front. Endocrinol. 3, 17 (2012).","journal-title":"Front. Endocrinol."},{"key":"1190_CR122","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/01.ju.0000136269.10161.32","volume":"172","author":"JM Kaufman","year":"2004","unstructured":"Kaufman, J. M. et al. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J. Urol. 172, 920\u2013922 (2004).","journal-title":"J. Urol."},{"key":"1190_CR123","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cncr.22438","volume":"109","author":"MF Sarosdy","year":"2007","unstructured":"Sarosdy, M. F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 109, 536\u2013541 (2007).","journal-title":"Cancer"},{"key":"1190_CR124","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.urolonc.2019.06.007","volume":"37","author":"M Kardoust Parizi","year":"2019","unstructured":"Kardoust Parizi, M. et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: a systematic literature review and meta-analysis. Urol. Oncol. 37, 637\u2013646 https:\/\/doi.org\/10.1016\/j.urolonc.2019.06.007 (2019).","journal-title":"Urol. Oncol."},{"key":"1190_CR125","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen, R. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310, 1829\u20131836 (2013).","journal-title":"JAMA"},{"key":"1190_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085805","volume":"9","author":"WD Finkle","year":"2014","unstructured":"Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9, e85805 (2014).","journal-title":"PLoS ONE"},{"key":"1190_CR127","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pcad.2024.04.001","volume":"85","author":"V Jaiswal","year":"2024","unstructured":"Jaiswal, V. et al. Association between testosterone replacement therapy and cardiovascular outcomes: a meta-analysis of 30 randomized controlled trials. Prog. Cardiovasc. Dis. 85, 45\u201353 https:\/\/doi.org\/10.1016\/j.pcad.2024.04.001 (2024).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"1190_CR128","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jsm.12464","volume":"11","author":"A Traish","year":"2014","unstructured":"Traish, A., Morgentaler, A. & Guay, A. Death by testosterone \u2014 we think not. J. Sex. Med. 11, 624\u2013629 (2014).","journal-title":"J. Sex. Med."},{"key":"1190_CR129","unstructured":"US Food and Drug Administration. FDA Briefing Document 2017: Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC). FDA https:\/\/fda.report\/media\/109435\/FDA-Briefing-Information-for-the-December-7--2017-Meeting-of-the-Bone--Reproductive-and-Urologic-Drugs-Advisory-Committee.pdf (2017)."},{"key":"1190_CR130","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf002","volume":"9","author":"KM Pencina","year":"2025","unstructured":"Pencina, K. M. et al. Testosterone replacement therapy and risk of COVID-19 and effect of COVID-19 on testosterone\u2019s treatment effect. J. Endocr. Soc. 9, bvaf002 (2025).","journal-title":"J. Endocr. Soc."},{"key":"1190_CR131","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004880","volume":"6","author":"R Sharma","year":"2017","unstructured":"Sharma, R. et al. Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J. Am. Heart Assoc. 6, e004880 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"1190_CR132","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/eurheartj\/ehv346","volume":"36","author":"R Sharma","year":"2015","unstructured":"Sharma, R. et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur. Heart J. 36, 2706\u20132715 (2015).","journal-title":"Eur. Heart J."},{"key":"1190_CR133","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2011.07.019","volume":"58","author":"C Ohlsson","year":"2011","unstructured":"Ohlsson, C. et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J. Am. Coll. Cardiol. 58, 1674\u20131681 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1190_CR134","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.maturitas.2013.04.012","volume":"75","author":"V Soisson","year":"2013","unstructured":"Soisson, V. et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas 75, 282\u2013288 (2013).","journal-title":"Maturitas"},{"key":"1190_CR135","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/EJE-13-0321","volume":"169","author":"V Muraleedharan","year":"2013","unstructured":"Muraleedharan, V. et al. Testosterone deficiency is associated with increased mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol. 169, 725\u2013733 (2013).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR136","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1136\/hrt.2010.195412","volume":"96","author":"CJ Malkin","year":"2010","unstructured":"Malkin, C. J. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96, 1821\u20131825 (2010).","journal-title":"Heart"},{"key":"1190_CR137","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.tem.2010.03.002","volume":"21","author":"TH Jones","year":"2010","unstructured":"Jones, T. H. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol. Metab. 21, 496\u2013503 (2010).","journal-title":"Trends Endocrinol. Metab."},{"key":"1190_CR138","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2337\/dc10-2339","volume":"34","author":"C Wang","year":"2011","unstructured":"Wang, C. et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular risk in men with type 2 diabetes. Diabetes Care 34, 1669\u20131675 (2011).","journal-title":"Diabetes Care"},{"key":"1190_CR139","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.mayocp.2024.08.008","volume":"99","author":"A Morgentaler","year":"2024","unstructured":"Morgentaler, A. et al. Androgen Society position paper on cardiovascular risk with testosterone therapy. Mayo Clin. Proc. 99, 1785\u20131801 (2024).","journal-title":"Mayo Clin. Proc."},{"key":"1190_CR140","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/andr.70062","volume":"14","author":"M Zitzmann","year":"2026","unstructured":"Zitzmann, M. et al. Cardiovascular safety of testosterone therapy \u2014 insights from the TRAVERSE trial and beyond: a position statement of the European Expert Panel for Testosterone Research. Andrology 14, 294\u2013302 (2026).","journal-title":"Andrology"},{"key":"1190_CR141","unstructured":"European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. EMA https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/no-consistent-evidence-increased-risk-heart-problems-testosterone-medicines_en.pdf (2014)."},{"key":"1190_CR142","unstructured":"US Food and Drug Administration. FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use (FDA, 2015)."},{"key":"1190_CR143","volume":"117","author":"IJ Strumpf","year":"1978","unstructured":"Strumpf, I. J., Reynolds, S. F., Vash, P. & Tashkin, D. P. A possible relationship between testosterone central control of ventilation and the Pickwickian syndrome [abstract]. Am. Rev. Respir. Dis. 117, 183 (1978).","journal-title":"Am. Rev. Respir. Dis."},{"key":"1190_CR144","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1743-6109.2007.00553.x","volume":"4","author":"HM Hanafy","year":"2007","unstructured":"Hanafy, H. M. Testosterone therapy and obstructive sleep apnea: is there a real connection? J. Sex. Med. 4, 1241\u20131246 (2007).","journal-title":"J. Sex. Med."},{"key":"1190_CR145","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3892\/or_00000962","volume":"24","author":"KA Johansen Taber","year":"2010","unstructured":"Johansen Taber, K. A. et al. Male breast cancer: risk factors, diagnosis, and management (review). Oncol. Rep. 24, 1115\u20131120 (2010).","journal-title":"Oncol. Rep."},{"key":"1190_CR146","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.eururo.2008.08.033","volume":"55","author":"C Wang","year":"2009","unstructured":"Wang, C. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur. Urol. 55, 121\u2013130 (2009).","journal-title":"Eur. Urol."},{"key":"1190_CR147","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-005-9074-y","volume":"96","author":"M Medras","year":"2006","unstructured":"Medras, M. et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res. Treat. 96, 263\u2013265 (2006).","journal-title":"Breast Cancer Res. Treat."},{"key":"1190_CR148","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.eururo.2021.08.014","volume":"80","author":"S Minhas","year":"2021","unstructured":"Minhas, S. et al. European Association of Urology guidelines on male sexual and reproductive health: 2021 update on male infertility. Eur. Urol. 80, 603\u2013620 (2021).","journal-title":"Eur. Urol."},{"key":"1190_CR149","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/andr.262","volume":"2","author":"G Rastrelli","year":"2014","unstructured":"Rastrelli, G., Corona, G., Mannucci, E. & Maggi, M. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology 2, 794\u2013808 (2014).","journal-title":"Andrology"},{"key":"1190_CR150","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(06)68614-5","volume":"367","author":"PY Liu","year":"2006","unstructured":"Liu, P. Y. et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367, 1412\u20131420 (2006).","journal-title":"Lancet"},{"key":"1190_CR151","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cen.13723","volume":"89","author":"M Grossmann","year":"2018","unstructured":"Grossmann, M. Hypogonadism and male obesity: focus on unresolved questions. Clin. Endocrinol. 89, 11\u201321 (2018).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-02005-0","volume":"25","author":"SH Orra","year":"2025","unstructured":"Orra, S. H. et al. Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis. BMC Urol. 25, 311 (2025).","journal-title":"BMC Urol."},{"key":"1190_CR153","doi-asserted-by":"publisher","first-page":"834","DOI":"10.21037\/tau.2016.07.10","volume":"5","author":"JJ Shoskes","year":"2016","unstructured":"Shoskes, J. J., Wilson, M. K. & Spinner, M. L. Pharmacology of testosterone replacement therapy preparations. Transl. Androl. Urol. 5, 834\u2013843 https:\/\/doi.org\/10.21037\/tau.2016.07.10 (2016).","journal-title":"Transl. Androl. Urol."},{"key":"1190_CR154","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jcem.85.12.7045","volume":"85","author":"RS Swerdloff","year":"2000","unstructured":"Swerdloff, R. S. et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85, 4500\u20134510 https:\/\/doi.org\/10.1210\/jcem.85.12.7045 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR155","first-page":"S22","volume":"6","author":"JD Dean","year":"2004","unstructured":"Dean, J. D., Carnegie, C., Rodzvilla, J. & Smith, T. Long-term effects of Testim\u00ae 1% testosterone gel in hypogonadal men. Rev. Urol. 6, S22\u2013S29 (2004).","journal-title":"Rev. Urol."},{"key":"1190_CR156","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2164\/jandrol.111.014308","volume":"33","author":"AS Dobs","year":"2012","unstructured":"Dobs, A. S. et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J. Androl. 33, 601\u2013607 https:\/\/doi.org\/10.2164\/jandrol.111.014308 (2012).","journal-title":"J. Androl."},{"key":"1190_CR157","doi-asserted-by":"publisher","first-page":"557","DOI":"10.4158\/EP161665.OR","volume":"23","author":"G Cunningham","year":"2017","unstructured":"Cunningham, G. et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr. Pract. 23, 557\u2013565 https:\/\/doi.org\/10.4158\/EP161665.OR (2017).","journal-title":"Endocr. Pract."},{"key":"1190_CR158","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/andr.12487","volume":"6","author":"S Arver","year":"2018","unstructured":"Arver, S. et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology 6, 396\u2013407 https:\/\/doi.org\/10.1111\/andr.12487 (2018).","journal-title":"Andrology"},{"key":"1190_CR159","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/andr.13108","volume":"10","author":"AW Pastuszak","year":"2022","unstructured":"Pastuszak, A. W. et al. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology 10, 209\u2013222 https:\/\/doi.org\/10.1111\/andr.13108 (2022).","journal-title":"Andrology"},{"key":"1190_CR160","doi-asserted-by":"publisher","DOI":"10.1111\/and.12801","volume":"50","author":"L Belkoff","year":"2018","unstructured":"Belkoff, L. et al. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: phase III open-label studies. Andrologia. 50, e12801 https:\/\/doi.org\/10.1111\/and.12801 (2018).","journal-title":"Andrologia."},{"key":"1190_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.02.1478","volume":"191","author":"A Winter","year":"2014","unstructured":"Winter, A. et al. Predictors of poor response to transdermal testosterone therapy in men with metabolic syndrome. J. Urol. 191, e528 https:\/\/doi.org\/10.1016\/j.juro.2014.02.1478 (2014).","journal-title":"J. Urol."},{"key":"1190_CR162","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/jsm.12411","volume":"11","author":"A Dobs","year":"2014","unstructured":"Dobs, A., Norwood, P., Potts, S., Gould, E. & Chitra, S. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index. J. Sex. Med. 11, 857\u2013864 https:\/\/doi.org\/10.1111\/jsm.12411 (2014). PMID:24283410.","journal-title":"J. Sex. Med."},{"key":"1190_CR163","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/tcrm.s3025","volume":"5","author":"N Bassil","year":"2009","unstructured":"Bassil, N., Alkaade, S. & Morley, J. E. The benefits and risks of testosterone replacement therapy: a review. Ther. Clin. Risk Manag. 5, 427\u2013448 https:\/\/doi.org\/10.2147\/tcrm.s3025 (2009).","journal-title":"Ther. Clin. Risk Manag."},{"key":"1190_CR164","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jsm.12114","volume":"10","author":"MJ Schoenfeld","year":"2013","unstructured":"Schoenfeld, M. J., Shortridge, E., Cui, Z. & Muram, D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J. Sex. Med. 10, 1401\u20131409 https:\/\/doi.org\/10.1111\/jsm.12114 (2013).","journal-title":"J. Sex. Med."},{"key":"1190_CR165","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jsm.12369","volume":"11","author":"JR Kovac","year":"2014","unstructured":"Kovac, J. R. et al. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices. J. Sex. Med. 11, 553\u2013562 https:\/\/doi.org\/10.1111\/jsm.12369 (2014).","journal-title":"J. Sex. Med."},{"key":"1190_CR166","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5489\/cuaj.5680","volume":"13","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. The My-T study: patient satisfaction and preference comparing topical and nasal testosterone therapies. Can. Urol. Assoc. J. 13, 384\u2013389 https:\/\/doi.org\/10.5489\/cuaj.5680 (2019).","journal-title":"Can. Urol. Assoc. J."},{"key":"1190_CR167","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/sxmrev\/qead003","volume":"11","author":"JA Miller","year":"2023","unstructured":"Miller, J. A., Nguyen, T. T., Loeb, C., Khera, M. & Yafi, F. A. Oral testosterone therapy: past, present, and future. Sex. Med. Rev. 11, 124\u2013138 https:\/\/doi.org\/10.1093\/sxmrev\/qead003 (2023).","journal-title":"Sex. Med. Rev."},{"key":"1190_CR168","doi-asserted-by":"publisher","DOI":"10.1177\/1756287220937232","volume":"12","author":"RS Swerdloff","year":"2020","unstructured":"Swerdloff, R. S. & Dudley, R. E. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. Ther. Adv. Urol. 12, 1756287220937232 https:\/\/doi.org\/10.1177\/1756287220937232 (2020).","journal-title":"Ther. Adv. Urol."},{"key":"1190_CR169","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1210\/clinem\/dgaa238","volume":"105","author":"RS Swerdloff","year":"2020","unstructured":"Swerdloff, R. S. et al. A new oral testosterone undecanoate formulation restores testosterone to normal concentrations in hypogonadal men. J. Clin. Endocrinol. Metab. 105, 2515\u20132531 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR170","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241241864","volume":"16","author":"JS Bernstein","year":"2024","unstructured":"Bernstein, J. S. & Dhingra, O. P. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Ther. Adv. Urol. 16, 17562872241241864 https:\/\/doi.org\/10.1177\/17562872241241864 (2024).","journal-title":"Ther. Adv. Urol."},{"key":"1190_CR171","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/andr.13153","volume":"10","author":"A DelConte","year":"2022","unstructured":"DelConte, A. et al. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology 10, 669\u2013676 https:\/\/doi.org\/10.1111\/andr.13153 (2022).","journal-title":"Andrology"},{"key":"1190_CR172","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/DHPS.S383130","volume":"15","author":"K Campbell","year":"2023","unstructured":"Campbell, K. et al. Safety aspects and rational use of testosterone undecanoate in the treatment of testosterone deficiency: clinical insights. Drug. Healthc. Patient Saf. 15, 73\u201384 https:\/\/doi.org\/10.2147\/DHPS.S383130 (2023).","journal-title":"Drug. Healthc. Patient Saf."},{"key":"1190_CR173","doi-asserted-by":"publisher","first-page":"762","DOI":"10.5534\/wjmh.230164","volume":"42","author":"MJ Rivero","year":"2024","unstructured":"Rivero, M. J. et al. Patient satisfaction with oral testosterone undecanoate in men who received prior testosterone therapy: an open-label, single-center clinical trial. World J. Mens Health 42, 762\u2013771 https:\/\/doi.org\/10.5534\/wjmh.230164 (2024).","journal-title":"World J. Mens Health"},{"key":"1190_CR174","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1210\/jcem.82.1.3640","volume":"82","author":"S Bhasin","year":"1997","unstructured":"Bhasin, S. & Bremner, W. J. Clinical review 85: emerging issues in androgen replacement therapy. J. Clin. Endocrinol. Metab. 82, 3\u20138 https:\/\/doi.org\/10.1210\/jcem.82.1.3640 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR175","doi-asserted-by":"crossref","unstructured":"Nieschlag E., Behre H. M. Testosterone therapy. In Andrology: Male Reproductive Health and Dysfunction 3rd edn (eds Nieschlag E., Behre H. M. & Nieschlag S.) 441\u2013446 (Springer, 2010).","DOI":"10.1007\/978-3-540-78355-8"},{"key":"1190_CR176","unstructured":"Joint Formulary Committee. BNF 74 (British National Formulary) September 2017 (Pharmaceutical Press, 2017)."},{"key":"1190_CR177","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.jsxm.2019.08.013","volume":"16","author":"M Gittelman","year":"2019","unstructured":"Gittelman, M., Jaffe, J. S. & Kaminetsky, J. C. Safety of a new subcutaneous testosterone enanthate auto-injector: results of a 26-week study. J. Sex. Med. 16, 1741\u20131748 https:\/\/doi.org\/10.1016\/j.jsxm.2019.08.013 (2019).","journal-title":"J. Sex. Med."},{"key":"1190_CR178","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/dta.1914","volume":"7","author":"G Forsdahl","year":"2015","unstructured":"Forsdahl, G. et al. Detection of testosterone esters in blood. Drug. Test. Anal. 7, 983\u2013989 https:\/\/doi.org\/10.1002\/dta.1914 (2015).","journal-title":"Drug. Test. Anal."},{"key":"1190_CR179","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1743-6109.2011.02570.x","volume":"9","author":"AR McCullough","year":"2012","unstructured":"McCullough, A. R. et al. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel\u00ae) insertion. J. Sex. Med. 9, 594\u2013601 https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02570.x (2012).","journal-title":"J. Sex. Med."},{"key":"1190_CR180","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1111\/j.1743-6109.2009.01513.x","volume":"6","author":"RK Cavender","year":"2009","unstructured":"Cavender, R. K. & Fairall, M. Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis. J. Sex. Med. 6, 3177\u20133192 https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01513.x (2009).","journal-title":"J. Sex. Med."},{"key":"1190_CR181","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1046\/j.1365-2265.1997.2521050.x","volume":"47","author":"DJ Handelsman","year":"1997","unstructured":"Handelsman, D. J., Mackey, M. A., Howe, C., Turner, L. & Conway, A. J. An analysis of testosterone implants for androgen replacement therapy. Clin. Endocrinol. 47, 311\u2013316 https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2521050.x (1997).","journal-title":"Clin. Endocrinol."},{"key":"1190_CR182","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1111\/jsm.12226","volume":"10","author":"RP Smith","year":"2013","unstructured":"Smith, R. P. et al. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism. J. Sex. Med. 10, 2326\u20132333 https:\/\/doi.org\/10.1111\/jsm.12226 (2013).","journal-title":"J. Sex. Med."},{"key":"1190_CR183","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13685530802351974","volume":"11","author":"C Mattern","year":"2008","unstructured":"Mattern, C., Hoffmann, C., Morley, J. E. & Badiu, C. Testosterone supplementation for hypogonadal men by the nasal route. Aging Male 11, 171\u2013178 https:\/\/doi.org\/10.1080\/13685530802351974 (2008).","journal-title":"Aging Male"},{"key":"1190_CR184","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/andr.12137","volume":"4","author":"AD Rogol","year":"2016","unstructured":"Rogol, A. D., Tkachenko, N. & Bryson, N. Natesto\u2122, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men. Andrology 4, 46\u201354 https:\/\/doi.org\/10.1111\/andr.12137 (2016).","journal-title":"Andrology"},{"key":"1190_CR185","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/JU.0000000000001078","volume":"204","author":"R Ramasamy","year":"2020","unstructured":"Ramasamy, R. et al. Effect of Natesto on reproductive hormones, semen parameters, and hypogonadal symptoms: a single center, open-label, single-arm trial. J. Urol. 204, 557\u2013563 https:\/\/doi.org\/10.1097\/JU.0000000000001078 (2020).","journal-title":"J. Urol."},{"key":"1190_CR186","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.euf.2018.08.009","volume":"4","author":"T Masterson","year":"2018","unstructured":"Masterson, T., Molina, M., Ibrahim, E. & Ramasamy, R. Natesto effects on reproductive hormones and semen parameters: results from an ongoing single-center, investigator-initiated phase IV clinical trial. Eur. Urol. Focus. 4, 333\u2013335 https:\/\/doi.org\/10.1016\/j.euf.2018.08.009 (2018).","journal-title":"Eur. Urol. Focus."},{"key":"1190_CR187","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1530\/eje.0.1500057","volume":"150","author":"RJM Ross","year":"2004","unstructured":"Ross, R. J. M. et al. Pharmacokinetics and tolerability of a bioadhesive buccal testosterone tablet in hypogonadal men. Eur. J. Endocrinol. 150, 57\u201363 https:\/\/doi.org\/10.1530\/eje.0.1500057 (2004).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR188","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2003-031946","volume":"89","author":"M Korbonits","year":"2004","unstructured":"Korbonits, M. et al. A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol. Metab. 89, 2039\u20132043 https:\/\/doi.org\/10.1210\/jc.2003-031946 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR189","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1464-410X.2011.10837.x","volume":"110","author":"WW Dinsmore","year":"2012","unstructured":"Dinsmore, W. W. & Wyllie, M. G. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 110, 162\u2013169 https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10837.x (2012).","journal-title":"BJU Int."},{"key":"1190_CR190","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1210\/jc.2003-031866","volume":"89","author":"C Wang","year":"2004","unstructured":"Wang, C. et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 3821\u20133829 https:\/\/doi.org\/10.1210\/jc.2003-031866 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1190_CR191","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.fertnstert.2014.06.004","volume":"102","author":"RD Wiehle","year":"2014","unstructured":"Wiehle, R. D. et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil. Steril. 102, 720\u2013727 https:\/\/doi.org\/10.1016\/j.fertnstert.2014.06.004 (2014).","journal-title":"Fertil. Steril."},{"key":"1190_CR192","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/JU.0000000000001520","volume":"205","author":"PN Schlegel","year":"2021","unstructured":"Schlegel, P. N. et al. Diagnosis and treatment of infertility in men: AUA\/ASRM guideline part II. J. Urol. 205, 44\u201351 https:\/\/doi.org\/10.1097\/JU.0000000000001520 (2021).","journal-title":"J. Urol."},{"key":"1190_CR193","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.juro.2014.03.089","volume":"192","author":"R Ramasamy","year":"2014","unstructured":"Ramasamy, R., Scovell, J. M., Kovac, J. R. & Lipshultz, L. I. Testosterone supplementation versus clomiphene citrate for hypogonadism: an age-matched comparison of satisfaction and efficacy. J. Urol. 192, 875\u2013879 https:\/\/doi.org\/10.1016\/j.juro.2014.03.089 (2014).","journal-title":"J. Urol."},{"key":"1190_CR194","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/bju.12363","volume":"112","author":"R Wiehle","year":"2013","unstructured":"Wiehle, R. et al. Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. 112, 1188\u20131200 https:\/\/doi.org\/10.1111\/bju.12363 (2013).","journal-title":"BJU Int."},{"key":"1190_CR195","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1089\/jomh.2014.0006","volume":"11","author":"RD Wiehle","year":"2014","unstructured":"Wiehle, R. D. et al. Enclomiphene citrate stimulates serum testosterone in men with low testosterone within 14 days. J. Mens Health 11, 196\u2013205 (2014).","journal-title":"J. Mens Health"},{"key":"1190_CR196","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/andr.12725","volume":"8","author":"M Awouters","year":"2020","unstructured":"Awouters, M., Vanderschueren, D. & Antonio, L. Aromatase inhibitors and selective estrogen receptor modulators: unconventional therapies for functional hypogonadism? Andrology 8, 1590\u20131597 (2020).","journal-title":"Andrology"},{"key":"1190_CR197","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/ejendo\/lvad099","volume":"189","author":"TH Jones","year":"2023","unstructured":"Jones, T. H., Dobs, A. S., Randeva, H., Moore, W. & Parkin, J. M. Leflutrozole in male obesity-associated hypogonadotropic hypogonadism: ph 2b double-blind randomised controlled trial. Eur. J. Endocrinol. 189, 297\u2013308 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17446651.2021.1863783","volume":"16","author":"J Fink","year":"2021","unstructured":"Fink, J., Schoenfeld, B. J., Hackney, A. C., Maekawa, T. & Horie, S. Human chorionic gonadotropin treatment: a viable option for management of secondary hypogonadism and male infertility. Expert Rev. Endocrinol. Metab. 16, 1\u20138 (2021).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"1190_CR199","first-page":"8","volume":"2","author":"KJ Campbell","year":"2021","unstructured":"Campbell, K. J., Sullivan, J. F. & Lipshultz, L. I. Updated protocols for optimizing sperm recovery after steroid use. Arch. Stem Cell Ther. 2, 8\u201311 (2021).","journal-title":"Arch. Stem Cell Ther."},{"key":"1190_CR200","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrendo.2015.112","volume":"11","author":"U Boehm","year":"2015","unstructured":"Boehm, U. et al. European consensus statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat. Rev. Endocrinol. 11, 547\u2013564 https:\/\/doi.org\/10.1038\/nrendo.2015.112 (2015).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1190_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22819","volume":"9","author":"AP Pichilingue","year":"2023","unstructured":"Pichilingue, A. P., Greene, D. N. & Krasowski, M. D. Falsely elevated serum testosterone measurements resulting from testosterone topical gel contamination of the venipuncture site: case series and retrospective review. Heliyon 9, e22819 https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22819 (2023).","journal-title":"Heliyon"},{"key":"1190_CR202","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1530\/EJE-11-0221","volume":"165","author":"F Saad","year":"2011","unstructured":"Saad, F. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocrinol. 165, 675\u2013685 https:\/\/doi.org\/10.1530\/EJE-11-0221 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"1190_CR203","unstructured":"Therapeutic Goods Administration. ANDROFORTE 5 testosterone 5% w\/v (50\u2009mg\/mL) cream tube (123764). Australian Government https:\/\/www.tga.gov.au\/resources\/artg\/123764 (2014)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01190-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01190-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01190-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:42:43Z","timestamp":1791826963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01190-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":203,"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01190-3","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"16 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H.J. declares travel grants and honoraria for educational lectures, webinars and advisory boards from Besins Healthcare; honoraria for advisory boards from Simple Pharma and Advanz; and a travel grant from Grunenthal. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}